Nicodemus Christopher F, Schultes Birgit C, Hamilton Brian L
AltaRex Corp, Waltham, MA 02451, USA.
Expert Rev Vaccines. 2002 Jun;1(1):35-48. doi: 10.1586/14760584.1.1.35.
This review identifies the role of antibodies in the field of therapeutic cancer vaccines. Ovarian cancer is used as a model to review advances in therapeutic vaccine development with a focus on antibodies as immunomodulators and antigen mimetics, highlighting research on B43.13 and ACA125. The interaction of biological immunomodulation and chemotherapy is discussed. Requirements of antigen processing and recent advances in the field of dendritic cell biology are critical to current understanding of potent immune response induction. Future directions including use of growth factors, adjuvants and cellular therapies to enhance effects may potentiate observed effects and provide clues for application in many cancers and beyond oncology.
本综述确定了抗体在治疗性癌症疫苗领域的作用。以卵巢癌为模型，回顾治疗性疫苗开发的进展，重点关注作为免疫调节剂和抗原模拟物的抗体，突出对B43.13和ACA125的研究。讨论了生物免疫调节与化疗的相互作用。抗原加工的要求以及树突状细胞生物学领域的最新进展对于当前对有效免疫反应诱导的理解至关重要。未来的方向包括使用生长因子、佐剂和细胞疗法来增强效果，这可能会增强观察到的效果，并为在许多癌症及肿瘤学以外的领域应用提供线索。
